Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00611 ...
Drug Name Butorphanol
Molecular Weight 327.4605
Molecular Formula C21H29NO2
CAS Number 42408-82-2
SMILES [H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1
External Links
DRUGBANK DB00611
T3DB T3D2837
PubChem Compound 6916249
PDR 1959
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 3.3 - 3.3 - DRUGBANK
Melting Point 273.0 ℃ 272-274 ℃ Monkovic, I. and Conway, T.T.; U.S. Patent 3,775,414; November 27,1973; Monkovic, I.,Wong, H. and Lim, G.; U.S. Patent 3,980,641; September 14, 1976; Pachter, IJ., Belleau, B.R. and Monkovic, I.; U.S. Patent 3,819,635; June 25,1974; and Lim, G. and Hooper, J.W.; U.S. Patent 4,017,497; April 12,1977; all assigned to Bristol-Myers Company.

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 65.0 % 60-70 % IM,intramuscular injection; DRUGBANK
Bioavailability 11.0 % 5-17 % PO, oral; DRUGBANK
Bioavailability 70.0 % 70±20 % nasal spray; The Pharmacological Basis of Therapeutics
C Max 1.4 ng/ml 1.4±0.6 ng/ml nasal spray; The Pharmacological Basis of Therapeutics
T Max 0.50 h 20-40 min IM,intramuscular injection; DRUGBANK
T Max 0.38 h 0.38(0.25-1) h nasal spray; The Pharmacological Basis of Therapeutics
Clearance 99.0 L/h 99±23 L/h intravenous injection, IV; young; DRUGBANK
Clearance 82.0 L/h 82±21 L/h intravenous injection, IV; DRUGBANK
Clearance 2.4 L/h/kg 40±10 ml/min/kg PO, oral; hydrolysis; normal,healthy; Male, men;  Female, women; adults; Elderly → ;hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ; The Pharmacological Basis of Therapeutics
Clearance 2.5 L/h/kg 41 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 603.0 L 305-901 L DRUGBANK
Volume of Distribution 12.0 L/kg 12±4 L/kg PO, oral; hydrolysis; normal,healthy; Male, men;  Female, women; adults; hepatopathy，LD ↑ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 12.0 L/kg 12 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 18.0 h ~18 h elimination half-life; DRUGBANK
Half-life 36.0 h ~36 h elimination half-life; moderate renal function; patients; DRUGBANK
Half-life 54.0 h ~54 h elimination half-life; intravenous injection, IV; hepatopathy，LD; patients; DRUGBANK
Half-life 4.8 h 4.8±1.6 h normal,healthy; adults; Male, men;  Female, women; chronic liver disease ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ; The Pharmacological Basis of Therapeutics
Half-life 4.8 h 4.8 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Eliminate Route 1.9 % 1.9±1.5 % Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 80.0 % ~80 % DRUGBANK
Protein Binding 81.5 % 80-83 % adults; normal,healthy; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Not Available

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1